Immunogenicity and Safety of the Coronavac Vaccine in Patients with Cancer Receiving Active Systemic Therapy
Cengiz Karaçin, Tülay Eren, Esra Zeynelgil, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, İbrahim Karadağ, Fatma Buğdaycı Başal, İrem Bilgetekin, Osman Sütçüoğlu, Ozan Yazıcı, Nuriye Özdemir, Ahmet Özet, Yeşim Yıldız, Seli̇n Aktürk Esen, Gökhan Uçar, Doğan Uncu, Bedia Dinç, Musa Barış Aykan, İsmail Ertürk, Nuri Karadurmuş, Burak Civelek, İ. Çelik, Yakup Ergün, Mutlu Doğan, Berna Öksüzoğlu
Abstract
Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Methods: This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic therapy for cancer. CoronaVac was administered as two doses (3 μg/day) on days 0 and 28. Antibody level higher than 1 IU/ml was defined as ‘immunogenicity.’ Results: The immunogenicity rate was 63.8% (30/47) in the entire patient group, 59.5% (25/42) in those receiving at least one cytotoxic drug and 100% (five of five) in those receiving monoclonal antibody or immunotherapy alone. Age was an independent predictive factor for immunogenicity (odds ratio: 0.830; p = 0.043). Conclusion: More than half of cancer patients receiving active systemic therapy developed immunogenicity.